Deep vein thrombosis, or DVT, is a potentially life-threatening blood clotting condition. If you’ve ever had DVT or been at risk for this condition, you’ve likely been given drugs to help break up the clot and to prevent future clots from forming.

O’Sullivan is an interventional radiologist — a physician who specializes in minimally invasive, targeted treatments. In mid-March at the Society of Interventional Radiology scientific meeting in Washington, D.C., he described the biggest DVT treatment ...

Avantec Vascular, a Nipro company, announced FDA 510(k) clearance of its thrombectomy system, which is intended for the treatme

Giving the anti-clotting drug rivaroxaban to patients for 12 weeks instead of the usual six after a blood clot in the lower leg reduces the risk of further clots developing up to two years after treatment, finds a trial published by The BMJ today.

SonoVascular announced today that it has completed the first close of its $6 million Series A financing round.

SonoVascular, Inc., a clinical stage medical device company focused on transforming the treatment of venous thromboembolism (VTE) with its SonoThrombectomy(TM) System, has completed the first close of its $6 million Series A preferred stock financing.

Deep vein thrombosis (DVT) is a serious condition that occurs when a blood clot forms in a vein, often in the deep veins of the legs, thigh or pelvis. Those clots can break loose, travel to the lungs and block blood flow, causing a pulmonary embolism.

There are several superficial vein thrombosis treatment options. A person’s symptoms and overall health can influence the type of treatment they receive. Superficial vein thrombosis (SVT), also known as superficial thrombophlebitis, refers to ...